Health Condition 1: Q278- Other specified congenital malformations of peripheral vascular system
Conditions
Interventions
Intervention1: bleomycin scerotherapy: Percutaneous intralesional injection sclerotherapy with bleomycin with maximum dose 15 mg in adult and 7.5mg for children every three weeks 1 to 6 sessions and a
Sponsors
Department of plastic surgery
Eligibility
Inclusion criteria
Inclusion criteria: Venous Malformation involving soft tissues all over body specifically involving superficial as well as deeper soft tissue
Exclusion criteria
Exclusion criteria: Interosseus venous malformation lymphatic malformation hemangiomas high flow venous malformations life threatning venous malformation due to visceral involvement immunosupression chronic infectious disease history of cancer in previous years pregnancy allergy to various sclerosants or lidocaine
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| primary efficacy end point of study will be reduction in size along with color swelling cosmetic results and patient opinion.Timepoint: 3 week 6 week 9 week 12 week 15 week 20 week 24 week 6 month 1 year | — |
Secondary
| Measure | Time frame |
|---|---|
| assess number of required embolization sessionsTimepoint: 3 sweek 6 week 9 week 12 week 15 week 18 week 21 week 24 week;complications of sclerosing agents.Timepoint: 3 weeks 6 weeks 9 weeks 12 weeks 12 weeks 15 weeks;review management strategies and outcomes for our cohort with previous reportsTimepoint: 6 months 1 year | — |
Countries
India
Contacts
Public ContactAshutosh shankhdhar
Patna medical college and Hospital
Outcome results
None listed